APP dp 1-6 APP dp 2-1 APP dp 1-2
Relative pThr231Tau/tTau (APP dp 1-2) and in an independent FAD APP dp patient line (APP dp 2-1) (mean±SEM, n³3).
Dosage effects are compared to the effect of simvastatin on APP dp 1-6 from figure 1d. *** p<0.001, **p<0.01, *p<0.05. 
F a t o s t a t i n F a t o s t a t i n
Effects of indicated compounds at same concentrations as in Figure 2 and a known toxic agent (Digitoxin) (five day treatment) on cell viability determined by (A) AQueous one cell viability assay (mean±SEM, n³3). (B) lactate dehydrogenase (LDH) released into the media (mean±SEM, n³3). (C) Effect of atorvastatin and atorvastatin washout on pThr231Tau/tTau ratio in APP dp 1-6. Neurons were treated for 5 days with DMSO or Atorvastatin and directly harvested, or after 5 days atorvastatin was washed-out and cells were harvested 2-4 days after wash out. (D) Purified neurons (NDC line B11 and B10) were treated for three days with atorvastatin or DMSO and harvested for quantitative mass spectrometry. In total three runs from three independent experiments were performed (two different experiments with B11 and one experiment with B10). All proteins that were increased >1.5 fold in all three runs were selected as hits and plotted by their effect on fold change (mean±sem). For complete dataset see Table   S4 . previously been shown to increase precursor levels, but in our cultures did not increase (rather modestly decrease) precursor levels. *In the AY-9944 treated neurons 7DHC and Cholesta-8,14-dien-3b-o accumulated as previously reported (Giera et al., 2007) . N³4 for all treatments, expect for desmosterol levels in atorvastatin treated samples, which were below detection in two out of four samples. ND=not detected. (P) 24-hydroxycholesterol (five day treatment) levels in media from APP dp 1-6 neuronal cultures treated with indicated compounds (mean±SEM, n³3). (Q-V) APP dp 1-6 neurons were treated with avasimibe (5µM) and lipid analysis was performed to measure (Q) total cholesterol (mean±sem, N≥8), three day treatment, (R) free cholesterol (mean±SEM, n³4), three day treatment (S) CE (mean±SEM, n³8) three day treatment (T) 24-hydroxycholesterol in media (mean±SEM, n³4) (five day treatment) and (U) desmosterol and (V) lathosterol both (mean±SEM, n³3) three day treatment. *** p<0.001, **p<0.01, *p<0.05. APP dp -3 copies of APP (genomic duplication)
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Log R Ratio Wildtype APP dp APP dp 1KO (allele 1) APP dp 1KO (allele 2) Relative pThr231Tau/tTau
S i m v a s t a t i n A t o r v a s t a t i n E f a v i r e n z
A P P d p ( A P P dp 1 -2 ) and an "A" insertion in the other allele, compared to wildtype sequence (APPdp) (upper box) generating a premature stop. (I) pThr231Tau/tTau ratio in isogenic purified APP dp (APP dp 1-2) and APP null (APPdp1KO) neurons (five days after sort) (mean±SEM, n³3). *** p<0.001, **p<0.01, *p<0.05. (A) The effect of Efavirenz (five day treatment, 10µM, APP dp 1-6 neurons) on Tau levels and (NSE) after treatment with DMSO or Atorvastatin (10µm) (five day treatment, APP dp 1-6 neurons). Image is a composite of different loading positions on same blot, stiches are indicated by vertical lines. (E) APP dp 1-6 neurons were treated for indicated time points with atorvastatin.
Supplemental
Cell lysates were analyzed by ELISA for pSer9GSK3b/ tGsk3b (mean±SEM, n³3). (F) APP dp 1-6 neurons were treated for 3 days with 25µM chloroquine (inhibitor of lysosomal acidification and autophagosomal degradation) or 5µM MG-132 (proteasomal inhibitor) and cell viability was determined (mean±sem, N≥3). (G) APP dp 1-6 neurons were treated for 3 days with 1.25nM okadaic acid (phosphatase inhibitor) and pGSK3b/GSK3b levels were determined by ELISA as a measure of phosphatase inhibition (mean±sem, N≥3). (H-I) APP dp 1-6 neurons were treated for 3 days with 10µM atorvastatin in the presence of 25µM chloroquine (H) or 5µM MG-132 (I). Lysates were collected and assessed by western blot staining with antibodies against (H) microtubule-associated protein 1A/1B-light chain 3 (LC3) to show inhibition of autophagic flux by chloroquine and staining with antibodies for (I) ubiquitin to show accumulation of ubiquitinated proteins in MG-132 treated samples. (J) APP dp 1-6 neurons were treated for 3 days with 5µM MG-132, fixed and stained with a total Tau antibody. (K) tTau/total protein levels and (L) pThr231Tau/total protein in APP dp neurons co-treated with atorvastatin (10µm) and the proteasome inhibitor (MG132, 5µM) for 3 days as measured by ELISA. Results are averages from two independent APP dp lines (APP dp 1-6 and 2-1) (mean±SEM, n³3 per line). (M) pThr231Tau/tTau levels in WT neurons co-treated with atorvastatin (10µm) and a proteasome inhibitor (MG132, 5µM) for 3 days as measured by ELISA. Results are averages from two independent WT lines (CV4a and line 151) (mean±sem, N≥3 per line). MG-132 is unstable in solution and was therefore added fresh every day in all experiments. (N) APP dp 1-6 Neurons were treated for indicated time points with 10µM atorvastatin and mRNA levels of proteasomal subunits PSMb5 and PSMC2 were determined by quantitative real-time polymerase chain reaction (RT-qPCR) and normalized over housekeeping genes (RPLP27) (mean±SEM, n³3).
(O) APP dp 1-6 neurons were treated for 5 days with DMSO, 10µM atorvastatin or Torin1 (an mTor inhibitor) and phosphorylation status of mTor target proteins was determined by western blot. Image is a composite of different loading positions on same blot, stiches are indicated by vertical lines. (P) APP dp 1-6 neurons were treated for indicated time points with DMSO or 10µM atorvastatin and phosphorylation status of the mTor target 4EBP1 was determined by ELISA (mean±SEM, n³3) (Q) Positive control for 4EBP ELISA. APP dp 1-6 neurons were treated for three days with insulin containing media or insulin-free media and phosphorylation status of the mTor target 4EBP1 was determined by ELISA (mean±SEM, n³3). *** p<0.001, **p<0.01, *p<0.05. iPSC-derived APP dp 2-1astrocytes were treated for three days with increasing concentrations of (A) simvastatin, (B) atorvastatin and (C) efavirenz and viability was determined (cell titer glo).
(D) APP null (APPdp1KO) neurons were treated for five days with increasing concentrations efavirenz and pThr231Tau/Tau levels, 24-hydroxycholesterol levels and viability was measured (mean±SEM, n³3). 
24-hydroxycholesterol
Relative 24-hydroxycholesterol Table depicts the absolute levels of free cholesterol (N=8) and total cholesterol (N=4) over protein corresponding to the relative levels plotted in figure 2d and e.
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